title: Elevation of synovial plasminogen activator activity after injection of interleukin-1 alpha into rabbit knee joint.
abstract: We investigated production of plasminogen activator (PA) and cartilage degradation induced by injection of recombinant human interleukin-1 (rhIL-1 alpha) in rabbit knees. Rabbits were injected intra-articularly (i.a.) with 100 ng rhIL-1 alpha and necropsied at 0, 3, 6, 18 and 54 h and synovial lavage and articular cartilage were collected. PA activity in the joint lavage was measured using Z-Lys-thiobenzyl ester as a substrate. Cartilage degradation was assessed by quantitating sulfated glycosaminoglycan (S-GAG) to hydroxyproline (Hyp) and appearance of keratan sulfate (KS) in synovial lavage by and ELISA. The PA activity in the lavage of IL-1 injected knees at 3, 6, and 18 h was elevated 8 to 10 fold compared to vehicle controls. At 54 h the activity declined to approximately one third of that seen at the earlier time points. KS in the joint lavage was highest at 18 h, suggesting proteoglycan degradation. The maximal loss of cartilage proteoglycan (S-GAG/Hyp) occurred by 54 h. These observations demonstrate that i.a. injection of IL-1 stimulated the production of PA activity within the rabbit joint. Since elevation of PA activity is followed by cartilage degradation, we investigated effect of anti-inflammatory agents on PA activity and cartilage degradation in this model. We found that triamcinolone, indomethacin and dexamethasone were able to suppress PA activity but not the cartilage degradation. These observations suggest that in this model of cartilage degradation suppression of PA is not sufficient to inhibit cartilage degradation.
authors.affiliation: Research Department, Ciba-Geigy Corporation, Summit, NJ 07901.
authors.forename: V S
authors.initials: VS
authors.lastname: Ganu
authors.forename: R L
authors.initials: RL
authors.lastname: Goldberg
authors.forename: V J
authors.initials: VJ
authors.lastname: Blancuzzi
authors.forename: D E
authors.initials: DE
authors.lastname: Wilson
authors.forename: J
authors.initials: J
authors.lastname: Doughty
authors.forename: R
authors.initials: R
authors.lastname: Melton
authors.forename: E
authors.initials: E
authors.lastname: O'Byrne
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology; D006614:Hindlimb; D007270:Injections, Intra-Articular; D007375:Interleukin-1 / Q000008:administration & dosage / Q000494:pharmacology*; D007592:Joint Diseases / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D010960:Plasminogen Activators / Q000378:metabolism*; D011509:Proteoglycans / Q000378:metabolism; D011817:Rabbits; D013256:Steroids; D013268:Stimulation, Chemical; D013582:Synovial Fluid / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007375:Interleukin-1; D011509:Proteoglycans; D013256:Steroids; D010960:Plasminogen Activators